Published in Br J Cancer on November 17, 2003
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin. Mol Cell Biol (2006) 1.79
Connections between epigenetic gene silencing and human disease. Mutat Res (2007) 1.72
Epigenetic regulation of estrogen receptor alpha gene expression in the mouse cortex during early postnatal development. Endocrinology (2009) 1.30
Epigenetics meets endocrinology. J Mol Endocrinol (2011) 1.30
Proteins that bind methylated DNA and human cancer: reading the wrong words. Br J Cancer (2008) 1.27
Rett syndrome-causing mutations in human MeCP2 result in diverse structural changes that impact folding and DNA interactions. J Biol Chem (2008) 1.12
Expression of Dnmt1, demethylase, MeCP2 and methylation of tumor-related genes in human gastric cancer. World J Gastroenterol (2004) 0.97
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Med (2015) 0.94
Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci (2010) 0.92
Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients. Br J Cancer (2011) 0.86
Regulation of estrogen receptor alpha gene expression in the mouse prefrontal cortex during early postnatal development. Neurogenetics (2012) 0.81
Epigenetic targeting in breast cancer: therapeutic impact and future direction. Drug News Perspect (2009) 0.80
Emerging Molecular and Biological Functions of MBD2, a Reader of DNA Methylation. Front Genet (2016) 0.80
Downregulation of microRNA-362-3p and microRNA-329 promotes tumor progression in human breast cancer. Cell Death Differ (2015) 0.79
Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential. BMC Syst Biol (2015) 0.75
Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients. BMC Cancer (2016) 0.75
Modifiers and Readers of DNA Modifications and Their Impact on Genome Structure, Expression, and Stability in Disease. Front Genet (2016) 0.75
MeCP2, a target of miR-638, facilitates gastric cancer cell proliferation through activation of the MEK1/2-ERK1/2 signaling pathway by upregulating GIT1. Oncogenesis (2017) 0.75
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell (1992) 27.80
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet (1999) 22.84
Methylation-induced repression--belts, braces, and chromatin. Cell (1999) 9.89
A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet (2001) 9.82
The power and the promise of DNA methylation markers. Nat Rev Cancer (2003) 9.32
Induction of tumors in mice by genomic hypomethylation. Science (2003) 8.86
Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet (2001) 8.64
Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell (1992) 8.10
Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol (1998) 7.61
MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell (1997) 6.45
Chromosomal instability and tumors promoted by DNA hypomethylation. Science (2003) 6.02
Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell (1989) 5.12
Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res (1993) 4.30
Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev (2001) 3.41
Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res (1992) 2.99
Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst (2000) 2.25
Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J Biol Chem (2002) 1.99
Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol (1978) 1.99
Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci U S A (2001) 1.93
The methyl-CpG binding protein MeCP2 is essential for embryonic development in the mouse. Nat Genet (1996) 1.93
Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene (2001) 1.64
Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum Mol Genet (2000) 1.61
Rett syndrome: methyl-CpG-binding protein 2 mutations and phenotype-genotype correlations. Am J Med Genet (2000) 1.53
Gene expression patterns vary in clonal cell cultures from Rett syndrome females with eight different MECP2 mutations. BMC Med Genet (2002) 1.53
The role of estrogen in mammary carcinogenesis. Ann N Y Acad Sci (1995) 1.35
Somatic mutation in MECP2 as a non-fatal neurodevelopmental disorder in males. Lancet (2000) 1.24
Methylation of the cyclin A1 promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent. Mol Cell Biol (2000) 1.14
Methylated DNA as a possible screening marker for neoplastic disease in several body fluids. Expert Rev Mol Diagn (2003) 1.06
MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland. Oncogene (2002) 1.02
Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid (2001) 1.01
Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Cancer (2000) 1.00
Correlation of DNA hypomethylation at pericentromeric heterochromatin regions of chromosomes 16 and 1 with histological features and chromosomal abnormalities of human breast carcinomas. Am J Pathol (2002) 0.94
Reduced mRNA expression of the DNA demethylase, MBD2, in human colorectal and stomach cancers. Biochem Biophys Res Commun (1999) 0.92
Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer. Br J Cancer (2001) 0.87
Proteins interacting with the mammalian estrogen receptor: proposal for an integrated model for estrogen receptor mediated regulation of transcription. J Cell Biochem (2001) 0.82
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 13.74
Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst (2000) 2.25
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 2.17
A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol (1999) 2.03
Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol (1998) 1.61
Behavioural and histopathological alterations in mice with cerebral malaria. Neuropathol Appl Neurobiol (2006) 1.57
Influence of use of a vascular closure device on incidence and surgical management of access site complications after percutaneous interventions. Eur J Vasc Endovasc Surg (2011) 1.50
[Surface temperatures of the hardening bone cement Palacos during fixation of metal endoprotheses in the femoral bone marrow space. Experimental study]. Arch Orthop Unfallchir (1969) 1.46
Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed (2003) 1.45
Effects of Taxol on choriocarcinoma cells. Am J Obstet Gynecol (1995) 1.39
[Endometrial hyperplasia--diagnosis and treatment]. Tidsskr Nor Laegeforen (1999) 1.38
Secondary leukaemias after etoposide. Lancet (1992) 1.38
Expression of 7F7-antigen, a human adhesion molecule identical to intercellular adhesion molecule-1 (ICAM-1) in human carcinomas and their stromal fibroblasts. Int J Cancer (1989) 1.31
Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update (2010) 1.26
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer (2000) 1.17
Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19. Lab Invest (2000) 1.15
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer (2012) 1.11
Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol (1996) 1.08
[Use of cooled metal endoprosthesis in hip surgery. Experimental studies]. Z Orthop Ihre Grenzgeb (1970) 1.07
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol (2003) 1.04
Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat (2001) 1.03
Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res (1997) 1.03
Anaphylactic reaction to ampicillin and severe complication in the fetus. Lancet (1991) 1.02
Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene (2010) 1.02
Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial. Br J Cancer (2012) 1.01
Nomogram prediction for overall survival of patients diagnosed with cervical cancer. Br J Cancer (2012) 1.01
Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood (1996) 1.00
Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet (2000) 0.97
Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol (1987) 0.96
Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res (1990) 0.96
Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene (2011) 0.96
Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer (1996) 0.94
Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J Mammary Gland Biol Neoplasia (2001) 0.94
Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res (1997) 0.94
Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells. J Natl Cancer Inst (1985) 0.94
Neopterin is an independent prognostic variable in females with breast cancer. Clin Chem (1999) 0.94
A psychometric study of complaints in chronic tinnitus. J Psychosom Res (1992) 0.93
Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. Br J Cancer (2011) 0.93
Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer (2000) 0.93
Ovarian cancer stem cells. Neoplasma (2012) 0.92
[Analysis of a dacrolith ]. Ophthalmologica (1987) 0.92
Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol (1994) 0.92
Use of IOTA simple rules for diagnosis of ovarian cancer: meta-analysis. Ultrasound Obstet Gynecol (2014) 0.92
Reliability of self-rated tinnitus distress and association with psychological symptom patterns. Br J Clin Psychol (1994) 0.92
Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. Int J Cancer (1996) 0.91
Relationship between quantity of silver stained nucleolar organizer regions associated proteins (Ag-NORs) and population doubling time in ten breast cancer cell lines. Pathol Res Pract (1992) 0.91
Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells. Int J Cancer (2001) 0.90
Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1. Am J Pathol (1999) 0.90
Human large granular lymphocytes and their relationship to natural killer cell activity in various disease states. Blood (1984) 0.90
Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res (2000) 0.90
Prognostic value of CD44 splice variant expression in ovarian cancer. Oncology (1995) 0.90
Practice of HER-2 immunohistochemistry in breast carcinoma in Austria. Pathol Oncol Res (2008) 0.90
[Urodynamic parameters before and following a vaginal incontinence operation]. Geburtshilfe Frauenheilkd (1986) 0.90
Mutual antagonism of TGF-beta and Interleukin-2 in cell survival and lineage commitment of induced regulatory T cells. Cell Death Differ (2012) 0.88
Peritoneum and tissues of the female reproductive tract as physiological sources of CA-125. Tumour Biol (1998) 0.88
High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. Br J Cancer (1997) 0.87
Pregnancies after adjustable gastric banding. Obes Surg (2001) 0.87
Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J Natl Cancer Inst (1986) 0.87
Leptin receptor in human term placenta: in situ hybridization and immunohistochemical localization. Placenta (1999) 0.86
Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients. Br J Cancer (2011) 0.86
Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Am J Pathol (1996) 0.86
Effects of retinoic acid and gamma-interferon on expression of retinoic acid receptor and cellular retinoic acid-binding protein in breast cancer cells. Cancer Res (1995) 0.86
Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematologic malignancies. J Interferon Res (1985) 0.85
Retraining therapy for chronic tinnitus. A critical analysis of its status. Scand Audiol (2000) 0.85
Regulation of transforming growth factor-beta secretion by human peritoneal mesothelial and ovarian carcinoma cells. Cytokine (2000) 0.85
Correlation of oestriol levels in saliva, plasma and urine of pregnant women. Acta Endocrinol (Copenh) (1985) 0.85
Effect of retinoic acid and 4-hydroxytamoxifen on human breast cancer cell lines. Biochem Pharmacol (1984) 0.85
Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature. Exp Clin Endocrinol Diabetes (2010) 0.85
[Tinnitus and psychological comorbidities]. HNO (2010) 0.85
Nitric oxide-dependent apoptosis in ovarian carcinoma cell lines. Gynecol Oncol (2001) 0.84
Lidocaine time- and dose-dependently demethylates deoxyribonucleic acid in breast cancer cell lines in vitro. Br J Anaesth (2012) 0.84
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. Gynecol Oncol (2006) 0.84
Hypomethylation along with increased H19 expression in placentas from pregnancies complicated with fetal growth restriction. Placenta (2010) 0.84
Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil Steril (1993) 0.84
DNA ploidy determination of early molar pregnancies by image analysis: comparison to histologic classification. Arch Pathol Lab Med (1998) 0.84